<DOC>
	<DOCNO>NCT00068393</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin gemcitabine , use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give doxorubicin together gemcitabine work treat patient locally recurrent metastatic unresectable renal cell carcinoma ( kidney cancer ) .</brief_summary>
	<brief_title>Doxorubicin Gemcitabine Treating Patients With Locally Recurrent Metastatic Unresectable Renal Cell Carcinoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient locally recurrent metastatic unresectable renal cell cancer sarcomatoid feature treat doxorubicin gemcitabine . - Determine progression-free survival overall survival patient treat regimen . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive doxorubicin intravenously ( IV ) gemcitabine IV 30 minute day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) day 2- 3-10 pegfilgrastim SC day 2 . Courses repeat every 2 week absence disease progression unacceptable toxicity . After 6 course , patient undergo MUGA scan . Patients stable* leave ventricular ejection fraction ( LVEF ) continue therapy . Patients reach total doxorubicin dose 450 mg/m^2 find unstable cardiac function abnormal LVEF continue therapy gemcitabine alone . NOTE : *Stable cardiac function define decrease 15 % LVEF absolute number LVEF least 35 % total function MUGA . Patients follow every 3 month 2 year every 6 month 1 year . ACTUAL ACCRUAL : A total 39 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically confirm renal cell carcinoma Features must sarcomatoid histology Locally recurrent metastatic disease amenable resection Measurable disease Must prior nephrectomy provide eligibility criterion meet , adequately recover recent surgery At least 4 week since prior radiotherapy recover ECOG performance status 01 WBC great 3,000/mm^3 absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Bilirubin less 1.5 mg/dL Aspartate aminotransferase ( AST ) less 2 time upper limit normal Creatinine great 2.0 mg/dL LVEF least low limit normal MUGA Negative pregnancy test Fertile patient must use effective contraception Other prior malignancy allow provided patient curatively treat disease free cancer Age 18 Diagnostic material kidney metastatic site biopsy available central pathologic review EXCLUSION CRITERIA : Prior treatment advance disease Previously irradiate lesion sole site disease patient prior radiation therapy Concurrent local radiotherapy pain control lifethreatening situation Myocardial infarction within past year Congestive heart failure within past year Significant ischemic valvular heart disease within past year Prior concurrent brain metastasis Concurrent serious medical illness would preclude study treatment Active infection would preclude study treatment Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Sarcomatoid</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Renal cell cancer</keyword>
	<keyword>Kidney cancer</keyword>
</DOC>